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The  objective  of  this  paper  is  to identify  and  articulate  ethical  considerations  to  help  guide  decision-
making  around  the  regulation  and  monitoring  of vaccines  post-licensure.  While  these  considerations  are
not intended  to be  an  exhaustive  account  of  the ethical  concerns,  they  can  facilitate  the  explicit  exam-
ination  of  ethical  issues  in  this  context.  We identify  the  protection  of  public  from  harm  as  the  primary
consideration,  and  identify  others  that help  in  the  discharging  of this  governmental  obligation.  Others
include:  transparency,  a publicly  acceptable  risk-beneﬁt  proﬁle,  public  trust,  minimization  of stigma,
and  special  obligations  to vulnerable  populations.  Regulators  and  researchers  can  use  these  ethical  con-thics
harmacoepidemiology
harmacovigilance
accines
siderations  to help  enhance  their  reasoning  and  to  improve  the  accountability  of their  decision-making.
These  considerations  can  be used  to inform  rational  deliberations  about  how  to balance  the  obligation
to  protect  the public  from  harm  with  other  relevant  considerations  such  as  the  need  to be transparent,
while  taking  into  account  the  contextual  features  of  the  situation.  Further  research  and  debate  on the
relevance  and  reﬁnement  of these  ethical  considerations  is  desirable.
© 2014  The  Authors.  Published  by  Elsevier  Ltd. This  is an  open  access  article  under  the CC  BY-NC-ND. Introduction
It has been over a decade since scholars began to articulate prin-
iples to guide the ethical analysis of issues in public health. Public
ealth ethics is now a robust ﬁeld of study including theoretical
nd practical considerations. However, there is a paucity of ethi-
al analysis about the issues associated with pharmaceutical and
accine regulation, particularly in the post-licensure context [1,2].
isk-beneﬁt analysis and policy-making are not a value-free enter-
rises, and involve important moral trade-offs. Often these ethical
rade-offs are not explicitly articulated, and remain invisible. In
his paper, we focus on the post-market monitoring of vaccines
nd identify ethical considerations arising from their monitoring
nd regulation. Many of the ethical considerations raised here will
e relevant to the post-market monitoring of drugs as well, but
ot necessarily to the pre-authorization phase of regulation and
esearch because of the distinguishing conditions of uncertainty
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44 College Street, Toronto, ON, Canada M4K1A1. Tel.: +001 416978 8824.
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264-410X/© 2014 The Authors. Published by Elsevier Ltd. This is an open access article unlicense  (http://creativecommons.org/licenses/by-nc-nd/3.0/).
and, at times, urgency [1] that obtain in the real-world setting of
vaccine use.
In the last decade there has been a growing acknowledgement
internationally that government bodies responsible for ensuring
the safety and effectiveness of pharmaceuticals and vaccines face
serious challenges when protecting the public from harm once
these products are used by people in the uncontrolled, real-world
context [4–7]. In most jurisdictions, regulation has been moving
towards an approach that takes into account the full lifecycle of
a drug or vaccine. This shift to lifecycle regulation has brought
with it a more comprehensive surveillance mandate and some-
times progressive licensing legislation as well as the need for
more evidence-generating capacity about how drugs and vaccines
behave outside of clinical trials. In some jurisdictions, such as
Canada, the shift to a lifecycle approach has been slow though,
and there have been calls for further changes to how regulators
safeguard the public’s health and public healthcare resources [8].
Within this post-market regulatory context, public health
agencies seek to increase vaccination uptake rates in the wake
of a growing trend for particular groups to be hesitant about
vaccination. Parents who  refuse or hesitate to vaccinate their
children have often chosen to focus more on the perceived risks
of adverse events from vaccination than on the risks of vaccine-
preventable diseases [9,10]. This trend has meant that vaccine
der the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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afety is foremost in the minds of many, and requires that regula-
ors do their utmost to ensure that vaccines are safe and effective
nd to engender the public’s trust in the regulatory system. In
ddition, Verweij and Dawson have argued that vaccines should
e held to higher standards of effectiveness and safety than other
harmaceutical products because most “vaccinations are offered
o healthy individuals as a measure to prevent possible future
arm” [11], especially in places where herd immunity is in effect
nd the chances of contracting diseases are low.
Given the recent shifts towards lifecycle regulation, and the
ncreasing reach of regulatory authorities to compel pharmaceu-
ical companies to conduct post-market research [12–15] this is
n opportune moment to ask what kinds of ethical concerns regu-
ators should be factoring into decision-making when it comes to
nsuring post-market vaccine safety and effectiveness. The set of
onsiderations articulated herein is not meant to explicitly address
he more narrow sub-set of concerns that pertain to the ethical con-
uct of research on and surveillance of post-market vaccines, such
s privacy, informed consent, etc. that have been considered else-
here [16–18]. Rather, the focus is on ethical considerations for
egulatory decision-making. First we shall articulate the consider-
tions, and then discuss their role within post-market monitoring
nd regulatory context.
. Identiﬁcation of ethical considerations
The considerations articulated herein are the result of bioethical
nalysis of the post-market regulatory context of vaccine regulation
n developed countries. In some cases, they are reformulations of
ccepted ethical principles discussed within the bioethics literature
11,19–21], and others are based upon bioethical analysis of recent
ontroversies around vaccines and their safety and efﬁcacy, such
s the human papilloma virus vaccine (HPVV) [22–24]. While there
as been important work done on the ethics of collective immu-
ization programs [11,19], vaccine safety and effectiveness is either
aken for granted as a starting point for the analyses, or identiﬁed
s an ethical principle but not examined in depth. This paper pro-
ides a more detailed ethical analysis of what needs to be taken
nto consideration ethically when regulators are conducting post-
arket vaccine monitoring and regulatory activities. For it is often
he case that when collective immunization programs are initiated,
specially in emergency circumstances, vaccines have limited real
orld data to support the claim that they are safe and effective, and
hus vaccination programs can function as de facto real-world vac-
ine trials [23]. It is therefore necessary to articulate some ethical
onsiderations, especially for cases where groups that are under-
epresented in pre-market clinical trials are the target of collective
mmunizations programs, such as was the case with the HPVV in
anada [22].
. Ethical considerations
1) Protection of the public from harm,
(a) highest quality of evidence possible,
b) anticipatory decision-making,
(c) duty to warn,
d) proportionate monitoring.
2) Transparency,
3) Publicly acceptable risk beneﬁt proﬁle,
4) Minimization of stigma
5) Special obligations to vulnerable populations,
6) Public trust.32 (2014) 7171–7174
3.1. Protection of the public from harm
The need to ensure that vaccines do not harm people because
of lack of safety or effectiveness is of paramount concern and is
the primary norm upon which monitoring activities are based.
This moral obligation is typically enshrined in the mandates of
government health and regulatory agencies. Regulators must also
ensure that harm is not caused by withdrawals of vaccines from
the market or by other restrictions that can cause channeling to
other unsafe drugs, vaccines or therapies [1], or by leaving special
sub-populations without alternatives for prevention or treatment.
The subsequent four ethical considerations should be considered
as related to protecting the public from harms that can arise from
both safety and effectiveness issues. They will not all always be rel-
evant, and some may  even be in tension with this consideration
and thus they will need to be weighed carefully by regulators.
3.1.1. Highest quality of evidence possible
Anticipating where problems may  arise with vaccines requires
the gathering of the best quality of evidence possible for use in
decision-making. In most cases, active surveillance and research
on all vaccinated populations is preferable to relying on passive
reporting, although under many regulatory systems this is seldom
feasible. Hard end-points should be used in studies where possible
to compensate for the problems associated with using soft end-
points in pre-market clinical trials, even though this may require
long-term surveillance in some cases [25]. The most ethically-
relevant aspect of this consideration, however, is the need to
minimize conﬂicts of interest that can introduce bias in research
design and reporting. Research that informs regulation ought to
have integrity: whenever possible, monitoring and research should
be free from industry inﬂuence [26,27]. Evidence about the com-
parative effectiveness of a vaccine is also necessary to evaluate
whether it is effective compared to existing vaccines or other
preventive actions or therapies [11]. This is needed in order to min-
imize the technological imperative to use the newest technologies
that can sometimes result in discarding other equally or more effec-
tive methods of preventing disease [28]. The sharing of safety and
effectiveness data across jurisdictions is also required and should be
facilitated by increasing the capacity to do so both within countries
and between them.
3.1.2. Anticipatory decision making
Regulators should take a proactive role in shaping safety and
effectiveness surveillance and research, and engage in preemptive
decision-making in order to prevent harm. Precautionary actions
such as withdrawal of a vaccine from the market, or the use of
black box warnings must be proportionate to the degree of scien-
tiﬁc certainty, the severity of possible harm, the size and nature of
the affected population, and the cost of the actions [29,30]. Deci-
sions should also be subject to review in light of new information
[20]. Anticipatory decision making can be fostered by the collec-
tion of the highest quality of evidence possible. It should be noted,
however, that the premature or complete withdrawal of a vaccine
from the market can also cause harm under certain circumstances,
and thus a precautionary approach may  not always be ethically
appropriate.
3.1.3. Duty to warn
Regulators have the duty to warn people when safety and/or
effectiveness issues are present with a vaccine. This can include
important reminders about waning immunity requiring a booster
in order that people remain protected from disease. For vaccines
where long-term effectiveness is unknown this is particularly
important, because other measures such as screening may  become
even more important for people in order to prevent morbidity and
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ortality. Warnings need to be communicated in a timely and
ppropriate manner. It must be noted, however, that the social
ontext of immunization programs may  be such that premature,
r overly alarmist warnings may  negatively impact vaccine accep-
ance in the population as a whole or in particular sub-populations.
hus, while there is a moral obligation to provide all relevant
nformation about vaccine safety and effectiveness to the public
n the interests of respecting individual autonomy and promoting
nformed consent, this must be balanced with the need to prevent
he spread of disease. Thus, the burden of disease needs to be taken
nto consideration when warning the public of possible harm when
vidence of harm is uncertain.
.1.4. Proportionate monitoring
This consideration speaks to the need to ensure that monitoring
ctivities are proportionate in scope to what is known about the
isk-beneﬁt proﬁle of a particular vaccine, as well as to the vulner-
bility of the population being immunized (see Section 3.5 below).
lso, the scale of use (is the vaccine being used in a collective
mmunization campaign?) should also be taken into consideration
hen deciding what kind of monitoring activities are necessary to
rotect the public from harm. Proportionality should inform deci-
ions around whether active or passive monitoring is needed, and
hether targeted or universal monitoring is needed.
.2. Transparency
Transparency requires that the rationale for regulatory deci-
ions, as well as the decisions themselves need to be communicated
o the public. In addition, risk communication around safety issues
ith vaccines needs to be made accessible and understandable in
 timely manner. Communicating to the public what is not known
bout the safety and effectiveness proﬁle of a vaccine is as impor-
ant, if not more important, than what is known [31]. Transparency
equires that information be communicated in a way  that can be
nderstood by the public. The need to be transparent with the pub-
ic is often thought to be in tension with the need to protect the
ublic from the harm in that transparency might result in a decline
n vaccine uptake. However, if public trust is damaged from a lack
f transparency, vaccine uptake more broadly may  be negatively
mpacted. Thus, there must be good reason for keeping safety and
ffectiveness information from the public, for regulators’ mistrust
f the public’s ability to understand information relating to vac-
ine safety may  result in a reciprocal mistrust in regulators on the
art of the public [31,32]. Transparency with industry, however,
round what vaccines may  be undergoing further safety or effec-
iveness studies may  compromise the independence (and therefore
ntegrity) of such research [8].
.3. Publicly acceptable risk-beneﬁt proﬁles
The process of deﬁning what constitutes a publicly-acceptable
evel of risk is a distinctly political responsibility and is one that
s ultimately based on values and priorities. Because there can be
mall direct beneﬁt to individuals due to a lower probability of con-
racting diseases where herd immunity has been achieved, there is
 low public tolerance for risks associated with vaccination [10].
here is a corresponding responsibility, therefore to maximize the
afety and effectiveness of a vaccine [11]. A high safety threshold
or vaccines must be maintained in order to achieve acceptable
evels of public uptake, especially for non-therapeutic vaccines.
n public health emergencies, the public may  be more likely to
ccept vaccines that have less evidence of safety and efﬁcacy [23],
ut more stringent monitoring is required by the need for propor-
ionate monitoring. In addition, comparative effectiveness requires
hat the vaccine present a risk-beneﬁt proﬁle that is preferable to32 (2014) 7171–7174 7173
other preventive modalities [11]. How to determine what is pub-
licly acceptable might in part be a function of considering uptake
levels, but in the case of compulsory vaccination this could be dif-
ﬁcult, and requires careful attention to avoid the abuse of public
health powers to compel individuals to be immunized.
3.4. Minimization of stigma
When public health agencies decide to put a population under
surveillance or to conduct research on particular groups, it can
potentially have a (re)stigmatizing effect on that population. Even
though it may  be less cost-effective, there may  be circumstances
where monitoring activities need to be less targeted in order to
avoid the undue stigmatization of groups vulnerable to being sin-
gled out as different in some way  [24]. This must be balanced
with the need to collect enough detailed information to protect
vulnerable groups from harm. Potentially stigmatizing research
or surveillance can include but is not limited to the collection of
data about vaccine uptake or acceptability and about behavioural
responses to vaccines (particularly for those vaccines that might
change behaviours that are themselves potentially stigmatizing,
e.g. sexual behaviour).
3.5. Special obligations to vulnerable populations
The routine exclusion of particular populations from pre-market
clinical trials creates a prima facie vulnerability in children, women,
older people, and aboriginal peoples owing to fact that evidence of
safety and effectiveness is often minimal or non-existent. In cer-
tain cases, it may  be necessary to focus monitoring activities on
these populations to determine if they are actually at greater risk of
harm. Harm could be a direct result from an adverse event following
immunization, diminished vaccine effectiveness, or behavioural
change that puts them at risk of harm [10,34]. In addition, the risk-
beneﬁt ratio is not the same for all sub-groups in a population:
differences in genotype and the health status of individuals can be
reasonably expected to render some populations more at risk from
adverse events and diminished effectiveness than others [10,33].
It may  also be the case that their inability to mount an effective
immune response to a vaccine also renders them more vulnerable
to infection from the disease public health agencies are trying to
prevent. In the common context of scarce resources and little capac-
ity for post-market monitoring activities, this consideration could
be used to justify the prioritization of surveillance and research on
these populations, in order to mitigate this kind of vulnerability and
in order to provide alternative protective measures where neces-
sary. However, this obligation needs to be considered in light of the
potentially stigmatizing effect of targeted monitoring activities.
3.6. Public trust
Many vaccinations are only effective if high levels of uptake
are achieved in order to get the protective effect of herd immu-
nity. This can only be accomplished if the public trusts public
health actors and regulators and distrust can be engendered when
the public feels that regulators and public health ofﬁcials are not
trustworthy. It is therefore important that conﬂicts of interest
on the part of researchers involved in pharmaco-epidemiological
research and regulators appropriately declare and manage con-
ﬂicts of interest, and that regulators take account of the potential
for bias in research ﬁndings by researchers with ties to indus-
try [26]. Anticipatory decision-making engenders public trust, as
opposed to reactive decision-making. Finally, being explicit about
how decisions around vaccine safety and effectiveness are made
and communicating with the public in a transparent fashion about
the risks and beneﬁts of vaccines is essential.
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. Discussion
Bioethical analysis of post-market vaccine monitoring and
egulation reveals the tensions that can exist between ethical con-
erns. Clearly, while the protection of the public from harm is of
aramount importance here, and a strong government responsi-
ility, careful balancing of the types of harm that can occur beyond
hose directly related to vaccine safety and efﬁcacy must occur.
hile we suggest that rational deliberation [21] must occur in
rder to ensure that the ethical tensions are acknowledged and
ddressed, we do not suggest that this set of considerations is
xhaustive or decisive. The empirical context is directly relevant to
ioethical deliberation, as there may  be morally relevant facts that
an inform how to weigh these considerations. Having said this, we
gree with Verweij and Dawson that despite the fact that decisions
re taken within a speciﬁc regulatory context in which there are
mpirical facts that need to be taken into account, “some agree-
ent can be reached about which general norms should guide”,
ven when agreement about the interpretation of the ethical con-
iderations remains contested [11]. We  thus propose these ethical
onsiderations as a starting place for ethical reﬂection and as a
eans to fostering deliberation, not closing down discussion.
. Conclusion
The utility of these considerations will require evaluation, as the
onceptual nature of this research will require further reﬁnement
hrough empirical research and input from a community of scholars
nd regulators and the public [3]. It is hoped that these consid-
rations will encourage regulators and researchers charged with
he post-market monitoring of vaccines to consider the explicit
rticulation of values in the decision-making and research-shaping
rocess in this context.
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